Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 378

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

A Review of the Pharmacokinetics and Pharmacodynamics of Remifentanil

Glass, Peter S. A., Gan, Tong J., Howell, Scott · 1999 · Anesthesia & Analgesia

Abstract

Over the past 30 yr, there have been marked improvements in the opioids available to clinicians. The major emphasis in the development of opioids has been increasing potency, increasing safety, and more suitable pharmacokinetics. The development of newer opioids is still directed at achieving these same goals; safety is aimed primarily at differentiating analgesic efficacy from respiratory depressant potency, and pharmacokinetics are aimed toward providing a titratable analgesic with rapid onset and rapid offset. Remifentanil has recently been approved in a number of countries for use as an opioid in the perioperative period, and initial results indicate that through its esterase-based metabolism, it will provide the pharmacokinetic advantages of a truly titratable opioid. Physiochemical Characteristics Remifentanil is a piperidine derivative, a 3-(4-methoxycarbonyl-4-[(L-oxopropyl)-phenylamino]-L-piperidine) propanoic acid, methyl ester. It is supplied as remifentanil hydrochloride, a white lyophilized powder. The present formulation also contains glycine. It is supplied as 1-, 2-, and 5-mg vials that must be reconstituted and diluted to 25- or 50-μg/mL solutions before administration. Once reconstituted, it has a pH of ±3.0 and a pKa of 7.07 (data on file, Glaxo Wellcome). It undergoes spontaneous degradation, but at a pH <4, it is stable for 24 h. It is lipid-soluble, with an octanol/water partition coefficient at pH 7.4 of 17.9 (i.e., similar to alfentanil, which has a partition coefficient of 13.14) (data on file, Glaxo Wellcome). Remifentanil is 92% protein-bound (data on file, Glaxo Wellcome). Opioid binding studies demonstrate that remifentanil has strong affinity for the μ-opioid receptor and less so for the δ- and κ-receptors (1,2). Remifentanil does not bind significantly to any other nonopioid receptors. Remifentanil is competitively antagonized by naloxone (3). The major metabolite of remifentanil is its carboxylic acid metabolite, remifentanil acid (4–6). Remifentanil acid similarly binds to μ-, δ-, and κ-receptors, but with much lower affinity. Binding studies indicate that the potency of this metabolite is 800–2000 times less potent than the parent compound (data on file, Glaxo Wellcome). In a study in dogs that investigated suppression of the electroencephalogram (EEG) by either remifentanil or remifentanil acid, the metabolite was 4600 times less potent than the parent compound. Animal studies indicate that the pharmacological properties of remifentanil are the same as other potent μ-opioid receptor agonists, such as alfentanil (1,7). Pharmacokinetics Remifentanil has a configuration very similar to the other piperidine derivatives, but it contains an ester linkage that makes it susceptible to metabolism by nonspecific esterases in blood and other tissues (Figure 1). In vitro studies in blood and in vivo studies in dogs demonstrated rapid and extensive metabolism of this compound by ester hydrolysis with a terminal elimination half-life of 3.8–8.3 min. In vitro testing indicates that its breakdown is unaltered by inhibition of plasmacholinesterase or by states of altered plasmacholinesterase function (8). Similarly, remifentanil will not alter the breakdown or duration of other esterase-metabolized compounds, such as succinylcholine or esmolol (9). Figure 1: The metabolic pathway of remifentanil. Remifentanil is metabolized by ester hydrolysis, primarily to remifentanil acid (GI90291), of which >80% is subsequently recovered in urine. Remifentanil acid is approximately 1/300 to 1/2000 the potency of the parent compound. Reprinted with permission from Glass PSA, Hardman D, Kamiyama Y, et al. Preliminary pharmacokinetics and pharmacodynamics of an ultra–short-acting opioid: remifentanil (GI87084B). Anesth Analg 1993;77:1031–40.Several studies describing the pharmacokinetics of remifentanil (4–6) have been performed in humans. In the initial assessment, remifentanil demonstrated a rapid onset, small volume of distribution, rapid redistribution, and clearance with a terminal elimination half-life of 8.8–40 min, compared with a terminal elimination half-life for alfentanil of 60–120 min (Table 1) (4–6). The rapid onset of remifentanil is demonstrated by its brief half-time for equilibration between plasma and its effect compartment (t1/2 ke0 of 1.0–1.5 min), which is similar to that of alfentanil (4,5). This short t1/2 ke0, together with its rapid redistribution, results in a time to peak drug effect after a bolus of 1.5 min. Again, this is similar to the rapid onset of effect seen with alfentanil, and it contrasts with the onset of peak effect observed after fentanyl 3–4 min or morphine 20 min. This rapid onset and offset of remifentanil and, thus, minimal latency between dose administration and observed effect should, in clinical practice, translate into an opioid that is very easy to titrate. Table 1: Pharmacokinetics of Remifentanil Compared with Alfentanil and FentanylPublished studies dif

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00000539-199910001-00003

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 378

Metadata

Authors
Glass, P. S. A., Gan, T. J., & Howell, S.
Venue
Anesthesia & Analgesia
Published
1999-10
Volume
89
Issue
4S
Pages
7
ISSN
0003-2999 (ISSN-L)
OpenAlex
W2091949720
Cited by
378
References
9
FWCI
14.17
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Review of the Pharmacokinetics and Pharmacodynamics of Remifentanil. https://app.cochat.ai/papers/10.1097/00000539-199910001-00003
The paper
Glass, P. S. A., Gan, T. J., & Howell, S. (1999). A Review of the Pharmacokinetics and Pharmacodynamics of Remifentanil. Anesthesia & Analgesia. https://doi.org/10.1097/00000539-199910001-00003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.